Beyond the target: implications of Wnt pathway inhibitors on bone health
Journal of Molecular Medicine · 2026-12 · 104 (1)
DOI: 10.1007/s00109-026-02697-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Molecular Medicine, online erschienen am 04.07.2026. Verfasst von Clement Nachef und 4 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology Department, Lariboisiere Hospital, Paris, France. clement.nachef@aphp.fr. Hauptthemen laut MEDLINE: Wnt Signaling Pathway, Bone and Bones. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Wnt signaling inhibitors are under investigation as potential therapies for conditions characterized by upregulated Wnt signaling, such as cancers, hematological disorders, and organ fibrosis. However, because the Wnt pathway is essential for bone homeostasis, its inhibition can adversely affect skeletal health. This review focuses on the bone-related off-target effects of Wnt inhibitors currently in clinical development, specifically those evaluated in Phase I and II trials with available published data. We found that inhibitors targeting upstream components of the pathway—such as Wnt ligands or receptors (e.g., porcupine inhibitors, Ipafricept, or Vantictumab)—frequently lead to bone-related adverse effects, including fractures and early trial termination. Co-administration of bisphosphonates may help mitigate these effects. In contrast, downstream inhibitors (e.g., PRI-724, niclosamide) have not been linked to bone toxicity, although this may reflect either underreporting or a genuinely lower skeletal impact. Further preclinical studies are warranted to better understand these differential effects. A thorough understanding of bone-specific risks is critical as Wnt signaling inhibitors continue to advance in clinical development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Rheumatology Department, Lariboisiere Hospital, Paris, France. clement.nachef@aphp.fr.
- Université de Paris, Paris, France. clement.nachef@aphp.fr.
- INSERM 1132 Unit, 2 Rue Ambroise Pare, 75010, Paris, France. clement.nachef@aphp.fr.
- Rheumatology Department, Lariboisiere Hospital, Paris, France.
- Université de Paris, Paris, France.
- INSERM 1132 Unit, 2 Rue Ambroise Pare, 75010, Paris, France.
Zitieren
APA
Nachef, C., Vanjak, A., Haÿ, E., Cohen-Solal, M., & Funck-Brentano, T. (2026). Beyond the target: implications of Wnt pathway inhibitors on bone health. Journal of Molecular Medicine, 104(1). https://doi.org/10.1007/s00109-026-02697-3
Vancouver
Nachef C, Vanjak A, Haÿ E, Cohen-Solal M, Funck-Brentano T. Beyond the target: implications of Wnt pathway inhibitors on bone health. Journal of Molecular Medicine. 2026;104(1). doi:10.1007/s00109-026-02697-3
BibTeX
@article{Nachef2026,
author = {Nachef, Clement and Vanjak, Arnaud and Haÿ, Eric and Cohen-Solal, Martine and Funck-Brentano, Thomas},
title = {Beyond the target: implications of Wnt pathway inhibitors on bone health},
journal = {Journal of Molecular Medicine},
year = {2026},
volume = {104},
number = {1},
doi = {10.1007/s00109-026-02697-3}
}
EUVIMED